Henry Schein Appoints Dan Daniel as Independent Chairman Following Stanley Bergman’s Retirement Henry Schein has announced a major leadership transition as its Board of Directors elected William K. “Dan” Daniel…
Merck Secures CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products…
Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk…
Veracyte to Present Practice-Changing Oncology Data at ASCO 2026 Highlighting Advances in Breast and Prostate Cancer Genomic Testing Veracyte announced that major new clinical data involving its Prosigna Breast and…
Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care Natera announced an extensive oncology research program for the 2026 Annual Meeting…
Vyriad has introduced G-Link, a modular platform designed to enhance T-cell targeted lentiviral vector delivery for both in vivo and ex vivo therapeutic applications. Vyriad, Inc. has introduced a new…
InSphero AG has acquired PhenoVista Biosciences, Inc. to strengthen its advanced 3D cell-based assay capabilities and expand translational research solutions. InSphero AG has announced the acquisition of PhenoVista Biosciences, Inc.,…
Jupiter Endovascular Reports Positive SPIRARE II Pivotal Trial Results at EuroPCR 2026 Jupiter Endovascular, Inc. announced positive topline results from its pivotal SPIRARE II clinical trial evaluating the company’s Vertex™…
Acuitas Therapeutics Showcases In Vivo CAR T Engineering and Lipid Innovations at ASGCT 2026 Acuitas Therapeutics concluded a prominent showing at the American Society of Gene & Cell Therapy 2026…
DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc.…
CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors, strengthening the company’s leadership and strategic expertise. CONMED Corporation has announced the appointment of two seasoned…